Originally posted by Bob Armstrong
View Post
Sadly, the pharma industry has done a number of "designed to fall studies" for cheap repurposed drugs in order to promote their program of all roads lead to expensive and profitable mass vaccination only. The most infamous was "Mehra et al" which actually had to be retracted from both the NEJM and the Lancet as it was based on data that literally did not exist. Data literally was made up out of thin air that was debunked by social media posts from all over the world
https://www.thelancet.com/journals/l...180-6/fulltext
The study above was sponsored by Gilead, on manufacturers of s toxic and useless drug called Remedeseivir that Dr. Fraudsci on no basis declared "the standard of care" even though the drug's side effects include acute Kidney failure in a large percentage of those that take it (initially it was a failed ebola drug for this reason.).
Here in this study, you mention https://www.nejm.org/doi/full/10.1056/NEJMoa2115869 the fraud is less blatant but fraud nonetheless. here are the major issues with the study. I found an article that gave this analysis of the data.
1) Young and healthy people were not included in the study and had to have at least one of the severe risk factors for disease
- Age over 50
- Hypertension requiring medical therapy
- Diabetes mellitus
- Cardiovascular disease
- Lung disease
- Smoking
- Obesity
- Organ transplantation
- Chronic kidney disease (stage IV) or receipt of dialysis
- Immunosuppressive therapy (receipt of ≥10 mg of prednisone or equivalent daily)
- Diagnosis of cancer within the previous 6 months
- Receipt of chemotherapy for cancer.
2) The group included both vaccinated and unvaccinated individuals The percentage of vaccinated participants in each group was not specified. Note that by choosing not to identify vaccination status as a confounding variable the authors are implying that vaccines are playing no role in preventing hospitalization.
3)Most noteworthy the authors wrote that the majority of the Placebo recipents ended up being hospitalized indicating that Ivermectin showed a benefit, exactly the opposite conclusion of the paper.
“100 patients (14.7%) in the ivermectin group had a primary-outcome event (composite of hospitalization due to the progression of COVID-19 or an emergency department visit of >6 hours that was due to clinical worsening of COVID-19), as compared with 111 (16.3%) in the placebo group
However, these data were not statistically significant given the size of the study.
This is how the authors were able to conclude there was no benefit to ivermectin use in preventing hospitalization in high-risk patients in their study.
4) Only 288 of 679 participants randomized to receiving the placebo reported 100% adherence to the study protocol. Nearly 400 didn’t. 391 people who didn’t take the placebo but did something else were included in two of the three calculations of ivermectin efficacy anyway.” Probably the placebo recipients knew the difference between Ivermectin and the placebo and went out and took ivermectin. In otherwords it was not a true blinded study.
5) Rather than pounding the final nail in the coffin around ivermectin’s utility in treating COVID, the NEJM study raises more questions.
- What would the effect have been if a higher dose shown to be effective were administered?
- What would be the benefit of this medicine in patients with no risk factors?
- How statistically significant would the results have been if more participants were enrolled?
- Why weren’t more participants enrolled as the study progressed given the emerging benefit of the drug and the absence of adverse events?
- Why did the investigators define a primary outcome with such different real-world implications (ER visits vs hospitalizations)?
- With less than 50% of the placebo arm adhering to the study protocol, why were their outcomes included in the analysis?
- What effect did vaccination status have on outcome? If this is the primary means endorsed to prevent hospitalization, why wasn’t vaccination status mentioned as a confounder?
- Did the investigators choose to limit the study as it became clear that an Ivermectin benefit would be too big to ignore?
Given these obvious issues with the study, it is becoming even more clear where the real story is: Neither The Globe and Mail, The Wall Street Journal or The New York Times are willing to pursue startling details around how corporate interests are corrupting scientific opinion as reported
Instead, these iconic journals chose to report on a scientific study on or prior to the day of publication using misleading headlines backed up by flimsy investigations conducted by journalists with no capacity to dissect the analysis or data.
Here’s a bigger question: Are they incompetent, or complicit, too? Consider this article that concludes that these large pharma sponsored publications cherrypick studies that are negative and ignore the vast majority of studies that are positive https://childrenshealthdefense.org/d...ic-ivermectin/
https://ivmmeta.com
Comment